Earnings call Recursion ended Q3 2025 with $785M in cash and no financing needs through 2027, aided by a 35% expense reduction and $40M in partnership inflows YTD. A $30M milestone from Roche ...

Recursion Pharmaceuticals Inc. (RXRX) reported its Q1 2025 financial results, revealing a slight miss on both earnings per share (EPS) and revenue forecasts. The company posted an EPS of -$0.5 against ...

Earnings call Recursion Pharmaceuticals reported a sharpened R&D focus, discontinuing three programs while advancing five+ high-potential assets. Early clinical data in FAP and CDK7 showed promise.

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid ...

Recursion narrowly beat EPS expectations, signaling effective cost management. Revenue fell short by 69.44%, raising concerns about growth prospects. The company maintains a strong cash position with ...

Hello, everybody, and welcome to Recursion's Third Quarter 2025 (L)earnings Call. My name is Chris Gibson. I'm the Co-Founder and current CEO of Recursion, and I'm so delighted to have you all joining ...

Recursion Pharmaceuticals, Inc. recently held its earnings call, which conveyed an optimistic sentiment. The company is experiencing strong leadership transitions, maintaining a robust financial ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...